| |
Baseline A1C ≥ 7.5 |
Baseline A1C <7.5 |
|
Characteristics |
Bromocriptine-QR
(N = 78) |
Placebo
(N = 44) |
Bromocriptine-QR
N = 254 |
Placebo
N = 119 |
|
Age |
56.4 ± 11.0 |
59.6 ± 10.9 |
59.9 ± 9.8 |
58.7 ± 10.3 |
| % Female |
52.6 |
43.2 |
57.5 |
24.0 |
Race/Ethnicity
% White
% Black
% Hispanic
% Other |
62.8
16.9
15.4
3.8 |
70.5
9.1
15.9
4.5 |
66.9
16.9
13.4
2.8 |
76.5
14.3
8.4
0.8 |
| Weight, kg |
94.4 ± 19.4 |
95.5 ± 20.5 |
94.3 ± 17.3 |
97.4 ± 19.2 |
| Body Mass Index, kg/m2 |
32.9 ± 5.1 |
32.7 ± 5.2 |
33.1 ± 5.1 |
33.6 ± 4.8 |
| Duration of diabetes mellitus, years |
7.8 ± 7.5 |
9.3 ± 7.6 |
6.9 ± 6.0 |
6.2 ±4.2 |
Screening thiazolidinedione
% Rosiglitazone
% Pioglitazone |
71.0
29.0 |
59.0
41.0 |
45.3
54.7 |
42.9
57.1 |
| Baseline Rosiglitazone Equivalent Dose, mg |
5.3 ± 2.3 |
5.9 ± 2.2 |
5.1 ± 2.3 |
5.4 ± 2.4 |
| Hemoglobin A1c ,% |
8.2 ± 0.6 |
8.4 ± 0.7 |
6.5 ± 0.6 |
6.4 ± 0.6 |
| Fasting plasma glucose, mg/dl |
172 ± 39.7 |
175 ± 44.1 |
125 ± 25 |
126 ± 26 |
| Systolic Blood Pressure, mmHg |
129 ± 13.4 |
131 ± 14.3 |
129 ± 14 |
128 ± 13 |
| Diastolic Blood Pressure, mmHg
Baseline Diabetic Therapy at Baseline |
76.9 ± 7.9 |
76.9 ± 9.6 |
77 ± 8 |
77 ± 9 |
% Taking thiazolidinedione only
% Taking TZD with Metformin
% Taking TZD with Sulfonylurea
% Taking TZD with Other Oral Diabetes Med |
17
60
22
3 |
18
43
39
2.3 |
37
50
14
0.4 |
40
30
4
0.8 |
Data presented as mean ± standard deviation (unless otherwise specified)